No abstract available
Keywords:
NAFLD/MASLD; bioinformatics; genetics; liver disorders; multi-omics; precision medicine.
PubMed Disclaimer
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment on
-
Editorial on the Research Topic Genetics and multi-omics approach in metabolic liver disorders
References
-
-
Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. (2023) 79:516–37. doi: 10.1016/j.jhep.2023.03.017
-
DOI
-
PubMed
-
-
Vargas M, Cardoso Toniasso SC, Riedel PG, Baldin CP, Dos Reis FL, Pereira RM, et al. Metabolic disease and the liver: A review. World J Hepatol. (2024) 16:33–40. doi: 10.4254/wjh.v16.i1.33
-
DOI
-
PMC
-
PubMed
-
-
Nogueira JP, Cusi K. Role of insulin resistance in the development of nonalcoholic fatty liver disease in people with type 2 diabetes: from bench to patient care. Diabetes Spectr. (2024) 37:20–8. doi: 10.2337/dsi23-0013
-
DOI
-
PMC
-
PubMed
-
-
Shi F, Zhao M, Zheng S, Zheng L, Wang H. Advances in genetic variation in metabolism-related fatty liver disease. Front Genet. (2023) :1213916. doi: 10.3389/fgene.2023.1213916
-
DOI
-
PMC
-
PubMed
-
-
Ramos-Lopez O. Multi-omics nutritional approaches targeting metabolic-associated fatty liver disease. Genes (Basel). (2022) 13:2142. doi: 10.3390/genes13112142
-
DOI
-
PMC
-
PubMed